PepGen

PEPGPhase 2

PepGen is advancing a pipeline of disease-modifying oligonucleotide therapeutics targeting the root cause of severe neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, the company aims to solve the critical delivery and uptake limitations of previous therapies, particularly in hard-to-reach tissues like heart and skeletal muscle. With a lead program in Phase 2 for DM1 and a robust discovery pipeline, PepGen is positioned to potentially transform treatment outcomes for patients with devastating genetic disorders. The company is publicly traded and led by an experienced team with deep expertise in rare disease drug development.

Market Cap

$324.8M

Focus

Drug Delivery

PEPG · Stock Price

USD 4.708.19 (-63.54%)

Historical price data

AI Company Overview

Technology Platform

Enhanced Delivery Oligonucleotide (EDO) platform: a proprietary technology using engineered cell-penetrating peptides to enable efficient, deep-tissue delivery of therapeutic oligonucleotides to skeletal, cardiac, and smooth muscle, as well as nerve cells.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
PGN-EDODM1	Myotonic Dystrophy 1	Phase 2
PGN-EDODM1	Myotonic Dystrophy 1	Phase 2
IV infusion	Duchenne Muscular Dystrophy (DMD)	Phase 2
PGN-EDO51	Duchenne Muscular Dystrophy	Phase 2
PGN-EDODM1 for infusion	Myotonic Dystrophy 1	Phase 1

Funding History

Total raised: $248.5M

IPO$108MUndisclosedMay 12, 2022

Series B$112.5MRA Capital ManagementDec 15, 2021

Series A$28MRA Capital ManagementSep 15, 2020

Opportunities

The primary growth opportunity is the successful development and commercialization of PGN-EDODM1 for DM1, a disease with no approved disease-modifying therapy.

Further expansion lies in leveraging the validated EDO platform to rapidly advance new candidates for other neuromuscular (e.g., DMD, CMT1A) and neurological diseases, creating a multi-product pipeline.

Strategic partnerships or out-licensing for specific indications or geographies could provide non-dilutive funding and accelerate development.

Risk Factors

Key risks include clinical trial failure of the lead candidate, which would jeopardize the company's value and platform validation.

The company faces intense competition from other biotechs developing advanced oligonucleotide delivery technologies.

As a pre-revenue public company, PepGen is also exposed to financial risks, including the need for future capital raises and market volatility affecting its stock price and ability to fund operations.

Competitive Landscape

PepGen competes in the oligonucleotide therapy space for neuromuscular diseases against companies like Dyne Therapeutics and Avidity Biosciences, which also employ conjugated delivery platforms. Its differentiation is based on the specific design of its EDO peptides, with claimed advantages in deep tissue penetration (especially cardiac muscle) and tolerability. In DMD, it faces competition from approved exon-skipping drugs (e.g., Sarepta) and gene therapies.